Skip to content

Archives

  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023

Categories

  • Blockchain
  • Business
  • Digital Marketing
  • Distro
  • Finance
  • Health
  • Home Improvement
  • Insurance
  • Jewelry
  • Marketing
  • Online Business
  • Real Estate
  • Small Business
  • Social Media
  • Startups
Skip to content
shopie mall

shopie mall

Your Ultimate Retail Destination

Subscribe
  • Distro
  • Social Media
  • Online Business
  • Finance
  • Startups
  • Digital Marketing
  • About Us
    • Advertise Here
    • Contact Us
    • Privacy Policy
    • Sitemap
  • Home
  • Digital Marketing
  • ARS Pharmaceuticals’ EpiPen Alternative Delayed US Approval – Two Analysts Offer Differing Views – ARS Pharmaceuticals (NASDAQ:SPRY)
ARS Pharmaceuticals’ EpiPen Alternative Delayed US Approval – Two Analysts Offer Differing Views – ARS Pharmaceuticals (NASDAQ:SPRY)

ARS Pharmaceuticals’ EpiPen Alternative Delayed US Approval – Two Analysts Offer Differing Views – ARS Pharmaceuticals (NASDAQ:SPRY)

Emily ClarkSeptember 21, 2023

ARS Pharmaceuticals’ EpiPen Alternative Delayed US Approval – Two Analysts Offer Differing Views – ARS Pharmaceuticals (NASDAQ:SPRY)

On Tuesday, The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc’s SPRY New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for adults and children ≥30 kg. 

Wedbush analysts remain bullish on the stock with an Outperform rating, but the price target was cut from $15 to $5.

The analysts remain puzzled by the FDA’s decision to go against the positive recommendation from the Pulmonary-Allergy Drug Advisory Committee, stating that neffy supports a favorable benefit-risk profile and issued a communication outlining an undisclosed deficiency last week resulting in the CRL. 

Although the CRL has pushed back the timelines for the approval and launch of neffy in the U.S., Wedbush still sees a clear path to approval in 2H 2024 with the repeat dose PK/PD study under NAC conditions as the sole gating factor. 

ARS believed that the repeat-dose NAC study would be a post-marketing requirement. 

Patient screening is already in progress, with the administration of the first dose anticipated shortly and the final patient expected to receive their dose before the end of 2023. 

Given the well-established safety profile of epinephrine, Wedbush considers the clinical risk associated with the trial to be minimal.

William Blair downgraded the stock to a Market Perform rating, noting that the Complete Response Letter would extend timelines and the heightened risk associated with conducting an extra head-to-head study.

Assessing the clinical and regulatory risks at this juncture is complex. The analyst awaits further clarity on the path forward and the availability of additional clinical data while maintaining that neffy is a notably distinct product and that ARS could establish itself as a key player in the self-administered epinephrine device market.

Price Action: SPRY shares are up 26.7% at $3.70 on the last check Thursday.

Alternative, Analysts, Approval, ARS, Delayed, Differing, EpiPen, NASDAQSPRY, Offer, Pharmaceuticals, Views

Post navigation

Previous: The Importance of Connecting Your Company to Your Product and Users
Next: 7 Ways to Drive It (And Get More Leads!)

Related Posts

The Art of Branding: Strategies to Create a Memorable Brand Identity

The Art of Branding: Strategies to Create a Memorable Brand Identity

September 16, 2024 Emily Clark
Website Development Company in Sydney: Transform Your E-commerce Platform Into a High-Performing Sales Engine

Website Development Company in Sydney: Transform Your E-commerce Platform Into a High-Performing Sales Engine

August 18, 2024September 11, 2024 Emily Clark
Struggling With Your Shopify Store? Here’s How To Turn It Around With The Right Advertising Agency

Struggling With Your Shopify Store? Here’s How To Turn It Around With The Right Advertising Agency

August 18, 2024September 21, 2024 Emily Clark

Recent Posts

  • How to Choose an Engagement Ring for a Bookworm
  • The Secret to a Smooth Garage Door Installation Every Homeowner Should Know
  • How to Get Bike Insurance for a Second-Hand Bike
  • The Art of Branding: Strategies to Create a Memorable Brand Identity
  • Website Development Company in Sydney: Transform Your E-commerce Platform Into a High-Performing Sales Engine

Categories

  • Blockchain
  • Business
  • Digital Marketing
  • Distro
  • Finance
  • Health
  • Home Improvement
  • Insurance
  • Jewelry
  • Marketing
  • Online Business
  • Real Estate
  • Small Business
  • Social Media
  • Startups

Archives

  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023

BL

Copyright All Rights Reserved | Theme: BlockWP by Candid Themes.